Allergen Specific Immunotherapy

被引:4
作者
Cekic, Sukru [1 ]
Sapan, Nihat [1 ]
机构
[1] Uludag Univ, Tip Fak, Cocuk Sagligi Hastaliklari Anabilim Dali, Cocuk Alerji Bilim Dali, Bursa, Turkey
来源
GUNCEL PEDIATRI-JOURNAL OF CURRENT PEDIATRICS | 2015年 / 13卷 / 01期
关键词
Allergy; immunotherapy; asthma; rhinitis;
D O I
10.4274/jcp.02419
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Allergen specific immunotherapy (SIT) is the only treatment that can provide a cure for allergic disorders. This treatment is based on development of immune tolerance by exposure to allergen in repetitive and increasing doses. It is tertiary to avoidance of allergen and pharmacotherapy. Allergens used for immunotherapy, must be confirmed by skin prick test or specific IgE and must be applied in supervision of allergy specialists. Studies show that immunotherapy, improve asthma symptoms, decreases drug consumption, prevent development of asthma in rhinitis patients and reduce new sensitizations. Common side effects diminished with the usage of standardized allergen solutions. It is contraindicated in severe asthma. Though it is recommended to avoid immunotherapy in patients using beta blockers and ACE inhibitors, immunotherapy can be considered in mandatory situations regarding possible benefits and harms. Most common ways of administration are subcutaneous and sublingual; new methods such as epicutaneous and intralymphatic injections are currently being studied.
引用
收藏
页码:46 / 55
页数:10
相关论文
共 66 条
[1]  
Abramson MJ, 2003, COCHRANE DB SYST REV, V4, DOI DOI 10.1002/14651858.CD001186
[2]   Mechanisms of allergen-specific immunotherapy [J].
Akdis, Cezmi A. ;
Akdis, Muebeccel .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2011, 127 (01) :18-27
[3]   Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells [J].
Akdis, M ;
Verhagen, J ;
Taylor, A ;
Karamloo, F ;
Karagiannidis, C ;
Crameri, R ;
Thunberg, S ;
Deniz, G ;
Valenta, R ;
Fiebig, H ;
Kegel, C ;
Disch, R ;
Schmidt-Weber, CB ;
Blaser, K ;
Akdis, CA .
JOURNAL OF EXPERIMENTAL MEDICINE, 2004, 199 (11) :1567-1575
[4]   T regulatory cells in allergy: Novel concepts in the pathogenesis, prevention, and treatment of allergic diseases [J].
Akdis, M ;
Blaser, K ;
Akdis, CA .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2005, 116 (05) :961-968
[5]   Increased activation-induced cell death of high IFN-γ-producing TH1 cells as a mechanism of TH2 predominance in atopic diseases [J].
Akkoc, Tunc ;
de Koning, Pieter J. A. ;
Ruckert, Beate ;
Barlan, Isil ;
Akdis, Mubeccel ;
Akdis, Cezmi A. .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2008, 121 (03) :652-658
[6]   Evaluation of near-fatal reactions to allergen immunotherapy injections [J].
Amin, HS ;
Liss, GM ;
Bernstein, DI .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2006, 117 (01) :169-175
[7]   Seasonal changes in suppressive capacity of CD4+ CD25+ T cells from patients with hayfever are allergen-specific and may result in part from expansion of effector T cells among the CD25+ population [J].
Anderson, A. E. ;
Mackerness, K. J. ;
Aizen, M. ;
Carr, V. A. ;
Nguyen, D. ;
Du Pre, F. ;
Durham, S. R. ;
Robinson, D. S. .
CLINICAL AND EXPERIMENTAL ALLERGY, 2009, 39 (11) :1693-1699
[8]  
Bahceciler NN, 2007, TURKIYE KLIN J INT M, V3, P30
[9]   The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3 [J].
Bennett, CL ;
Christie, J ;
Ramsdell, F ;
Brunkow, ME ;
Ferguson, PJ ;
Whitesell, L ;
Kelly, TE ;
Saulsbury, FT ;
Chance, PF ;
Ochs, HD .
NATURE GENETICS, 2001, 27 (01) :20-21
[10]   Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001 [J].
Bernstein, DI ;
Wanner, M ;
Borish, L ;
Liss, GM .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2004, 113 (06) :1129-1136